Primary Multidrug Resistant Tuberculosis and Utility of Line Probe Assay for Its Detection in Smear-Positive Sputum Samples in a Tertiary Care Hospital in South India

<table class="table-group" id="tab1"><tr><td><table class="table"><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td class="align_left"> </td><td class="align_left">Intensive phase</td><td class="align_left">Continuation phase</td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td class="align_left">Category I <br/>(DOTS)</td><td class="align_left">Rifampicin + INH + ethambutol + pyrazinamide <br/>(thrice a week for 2 months)</td><td class="align_left">Rifampicin + INH <br/>(thrice a week for 4 months)</td></tr><tr><td class="align_left">Category IV <br/>(DOTS<i>plus</i>)</td><td class="align_left">Kanamycin + ofloxacin (levofloxacin) + ethionamide + pyrazinamide + ethambutol + cycloserine <br/>(daily for 6–9 months)</td><td class="align_left">Ofloxacin (levofloxacin) + ethionamide + ethambutol + cycloserine <br/>(daily for 18 months)</td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

Category I (DOTS) and category IV (DOTS<i>plus</i>) regimen advocated under RNTCP for new TB and MDR TB patients, respectively.

Journal of Pathogens

tab1

Table 1

Table 1: Primary Multidrug Resistant Tuberculosis and Utility of Line Probe Assay for Its Detection in Smear-Positive Sputum Samples in a Tertiary Care Hospital in South India 

Table 1 | Primary Multidrug Resistant Tuberculosis and Utility of Line Probe Assay for Its Detection in Smear-Positive Sputum Samples in a Tertiary Care Hospital in South India 